Pharmacokinetic Profile of Two Active Dipyrone Metabolites, 4-Methylaminoantipyrine (MAA) and 4-Aminoantipyrine (AA), Following Intravenous Administration in Dogs: A Preliminary Study
2025
Andressa N. Mouta | Kathryn N. Arcoverde | Naftáli S. Fernandes | Yanna D. B. Passos | Caio V. A. de Oliveira | Robson A. Honorato | Gabriel Araujo-Silva | Valéria V. de Paula
This study aimed to determine the pharmacokinetic profile of the active dipyrone metabolites, 4-methylaminoantipyrine and 4-aminoantipyrine, following intravenous administration in dogs. Eleven mixed-breed dogs received a 25 mg·:kg&minus:1 dipyrone dose and blood samples were collected at 0, 5, 15, 30 and 45 min, as well as at 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 h. Plasma concentrations of both metabolites were analyzed by ultra-performance liquid chromatography coupled to mass spectrometry. The PKSolver 2.0 and GraphPad Prisma 10 software programs were used for pharmacokinetic and statistical analyses, applying a Principal Component Analysis for MAA and descriptive statistics for both metabolites. Two groups were noteworthy concerning MAA: slow metabolizers (SM) and normal/rapid metabolizers (NM). Significant differences were observed between half-life (T½:) and MRT0_inf :obs values between the MAA groups. The T½: and MRT0_info :obs were 44.44 ±: 11.74 and 32.62 ±: 16.53 h for the SM group and 11.25 ±: 5.37 and 7.44 ±: 4.25 h for the NM group, respectively. The Cmax of AA was 2.80 ±: 1.43 µ:g mL&minus:1. Metabolites were detectable for 48 h in all animals for MAA and seven for AA. These findings suggest that metamizole reaches analgesia plasma concentrations associated with cyclooxygenase inhibition with few adverse effects in dogs. However, additional pharmacogenetic and pharmacotherapeutic monitoring studies are required.
显示更多 [+] 显示较少 [-]